The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
February 12th 2025
Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.
February 10th 2025
February 6th 2025
Other Notable Emerging Lipid-Lowering Treatments
May 23rd 2024Erin Michos, MD, highlights several notable emerging lipid-lowering treatments, including bempedoic acid, the ANGPTL3 inhibitor evinacumab, the MTP inhibitor lomitapide, the ApoB-100 inhibitor mipomersen, and the ApoC-III degradation molecules volanesorsen and olezarsen.
Evaluating Safety of Novel LDL Management Mechanism
May 15th 2024Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.
Innovations in Small Interfering RNA (siRNA) Therapy
May 8th 2024Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Ongoing Lp(a) Trials and Clinical Approaches to Treatment
May 8th 2024Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.
Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
May 1st 2024Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.